Skip to main content

Table 4 Bivariable analysis of TLE3 with clinical and pathologic prognosticators

From: TLE3 as a candidate biomarker of response to taxane therapy

 

CCIH

RPCI

 

TLE3

Clinical variable

TLE3

Clinical variable

Variable

HR

P value

HR

P value

HR

P value

HR

P value

Age

0.114

0.038

1.002

0.94

0.15

0.02

0.98

0.52

Tumor size

0.125

0.047

1.026

0.91

0.13

0.01

1.18

0.07

Node status

0.123

0.045

0.423

0.22

0.14

0.02

1.04

0.21

Stage

0.010

0.035

2.24

0.25

0.15

0.02

1.58

0.25

Grade

0.125

0.048

0.95

0.83

0.15

0.02

0.61

0.29

Ki67

0.118

0.041

0.82

0.74

0.09

0.03

0.53

0.45

EGFR

0.09

0.028

2.1

0.37

0.15

0.02

0.63

0.66

ER

0.116

0.042

0.956

0.94

NA

NA

NA

NA

HER2

0.099

0.028

5.92

0.01

NA

NA

NA

NA

  1. TLE3 was tested for independence in the Clearview Cancer Institute in Huntsville (CCIH) and Roswell Park Cancer Institute (RPCI) triple-negative cohorts with a range of standard clinical prognosticators. Independence was tested by placing TLE3 in a Cox proportional hazards model with each of the above variables. In all equations, TLE3 remained a significantly independent predictor of taxane sensitivity (P values ranging from 0.008 to 0.048, hazard ratios [HRs] from 0.05 to 0.29). In the validation cohort, tumor size, number of metastatic nodes, and stage remain independent prognosticators to TLE3+, while age trends in the right direction. Grade and Ki67 are not independent prognosticators; this is likely due to the fact that the cohort consists almost entirely of high-proliferative tumors. EGFR, epidermal growth factor receptor; ER, estrogen receptor; NA, not applicable.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us